OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
The new research and development capacities set the stage for completion of product development for LEON’s manufacturing devices and will be used to showcase the devices and provide process development services to clients using LEON’s equipment.
LEON (eon-nanodrugs GmbH) announced on April 27, 2023 that the establishment of their own lab facilities at IZB (Start-Up Center for Biotechnology) in Munich has been initiated. The new research and development capacities set the stage for completion of product development for LEON’s manufacturing devices and will be used to showcase the devices and provide process development services to clients using LEON’s equipment.
The product platform at LEON is built on their proprietary, innovative FR-JET technology that enables a huge efficiency increase in the formulation process of active ingredients into nanodrug carriers, like lipid nanoparticles (LNPs). Further, their devices, the NANOme and NANOus, are designed for aseptic processing, GMP-compliance, and quick scale-up. NANOme is intended for small-scale, individual patient and clinical trial-size production, whereas NANOus is a fully automated, aseptic device enabling the LNPencapsulation of APIs from medium- to large-scale with high throughput using process analytical technology.
“We are truly excited about moving into the IZB. As one of the key biotech hubs in Germany, the IZB provides not only lab facilities, but also an unparalleled environment to foster innovation and growth,” said Setu Kasera, PhD, head of Science and Engineering, in a press release. “The local proximity to biotech start-ups, academia, VCs, and Big Pharma creates an ecosystem that facilitates networking in- and outside of your peer group, setting the stage for future cooperations and partnerships. We are looking forward to using our new capacities to complete the development of our devices for the market, while we pursue and build on opportunities for collaborations by providing access to our devices and process development services.”